Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Real‐world on‐treatment and initial treatment absolute risk differences for dabigatran vs warfarin in older US adults

Pharmacoepidemiology and Drug Safety(2020)10.1002/pds.5069Source: DataRank Database

Real‐world on‐treatment and initial treatment absolute risk differences for dabigatran vs warfarin in older US adults is a research paper published in Pharmacoepidemiology and Drug Safety (2020). On theSindex it has a DataRank of 0. It has been cited 7 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access7 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (6 grants)Impact (FWCI 0.46)OA: greenTopics (70)IDs (PubMed, PMC, OpenAlex)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (6)

Til Stürmer‎ORCID,Jessie K. Edwards ORCID,Charles Poole,Ross J. Simpson ORCID,Jennifer L. Lund ORCID

Live enrichment

PubMed:32666678 PMC:PMC8356559 OpenAlex:https://openalex.org/W3043771751

National Institute on Aging

Grant: R01 AG056479

National Institutes of Health

Grant: K01AI125087

National Institutes of Health

Grant: UL1TR002489

National Institutes of Health

Grant: 3UL1TR002489-02S1

North Carolina Translational and Clinical Science Institute (NC TraCS)

National Institutes of Health

Grant: 1K01AI125087-01A1

Comparative effectiveness of tailored HIV treatment plans and mortality

National Institutes of Health

Grant: 1R01AG056479-01

Propensity scores and preventive drug use in the elderly

FWCI

0.46

Citation Percentile

0.7%

Citation Trend

2021

2023

2024

2025

greenLicense: Wiley Online Library User Agreement

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/8356559

publisherhttps://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fpds.5069

publisherhttps://onlinelibrary.wiley.com/doi/pdf/10.1002/pds.5069

publisherhttps://onlinelibrary.wiley.com/doi/full-xml/10.1002/pds.5069

Fields of Study

Atrial Fibrillation Management and OutcomesPharmacogenetics and Drug MetabolismMedication Adherence and Compliance03 medical and health sciences0302 clinical medicineAge FactorsAgedAged, 80 and overAntithrombinsAtrial FibrillationDabigatranDrug-Related Side Effects and Adverse ReactionsFemaleGastrointestinal HemorrhageHealth Services for the AgedHumansMaleMedicareRisk FactorsStrokeUnited StatesWarfarin

MeSH Terms

DabigatranAge FactorsAgedAged, 80 and overAntithrombinsAtrial FibrillationFemaleMedicareHealth Services for the AgedGastrointestinal HemorrhageHumansMaleRisk FactorsUnited StatesWarfarinStrokeDrug-Related Side Effects and Adverse Reactions

Keywords

DabigatranMedicineWarfarinAtrial fibrillationStroke (engine)Internal medicineGastrointestinal bleedingObservational studyInverse probability weightingNumber needed to harmEmergency medicineConfidence intervalRelative riskNumber needed to treatPropensity score matchingAnticoagulantsStrokeOlder AdultsAged, 80 and overMaleDrug-Related Side Effects and Adverse ReactionsHealth Services for the AgedAge FactorsMedicareAntithrombinsUnited StatesRisk FactorsHumansFemaleGastrointestinal HemorrhageAged

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being